QTRX Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

37.94M

+7.91%

-0.480

+60%

36.69M

+20.95%

-0.447

-15.72%

39.00M

+59.34%

-0.423

-45.02%

Estimates Revision

The market is revising No Change the revenue expectations for Quanterix Corporation (QTRX) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 39.92%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Up

+39.92%

In Past 3 Month

3 Analyst Rating

Wall Street analysts forecast QTRX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for QTRX is 6.00 USD with a low forecast of 5.00 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

0 Buy

3 Hold

0 Sell

Hold

Current: 7.360

Low

5.00

Averages

6.00

High

7.00

Current: 7.360

Low

5.00

Averages

6.00

High

7.00

Canaccord

Buy -> Hold

downgrade

$12 -> $5

2025-08-11

Reason

Canaccord

Price Target

$12 -> $5

2025-08-11

downgrade

Buy -> Hold

Reason

Canaccord downgraded Quanterix to Hold from Buy with a price target of $5, down from $12. following the Q2 miss. The firm cites a lack of near-term visibility and catalysts to move the shares higher for the downgrade. Quanterix's results were impacted by increasing headwinds in biopharma and continued National Institutes of Health funding uncertainty, the analyst tells investors in a research note.

Nephron Research

Buy

Hold

downgrade

2025-07-09

Reason

Nephron Research

Price Target

2025-07-09

downgrade

Buy

Hold

Reason

Nephron Research downgraded Quanterix to Hold from Buy with an $8 price target.

Morgan Stanley

Equal Weight

downgrade

2025-06-02

Reason

Morgan Stanley

Price Target

2025-06-02

downgrade

Equal Weight

Reason

Morgan Stanley lowered the firm's price target on Akoya Biosciences (AKYA) to $1.14 from $3 and keeps an Equal Weight rating on the shares. The firm is updating its model for Akoya's Q1 results and the amended merger agreement proposed by Quanterix (QTRX), the analyst tells investors.

Scotiabank

Sung Nam

Buy

Maintains

$28 → $18

2025-03-25

Reason

Scotiabank

Sung Nam

Price Target

$28 → $18

2025-03-25

Maintains

Buy

Reason

Scotiabank analyst Sung Ji Nam lowered the firm's price target on Quanterix to $18 from $28 and keeps an Outperform rating on the shares. Despite the relatively stronger revenue growth performance compared to its peer group, the company's shares underperformed over the last year, the analyst tells investors. While the firm thinks the operating synergy targets are reasonable, it is less certain about the top line growth potential.

Canaccord Genuity

Kyle Mikson

Strong Buy

Maintains

$20 → $15

2025-03-18

Reason

Canaccord Genuity

Kyle Mikson

Price Target

$20 → $15

2025-03-18

Maintains

Strong Buy

Reason

Canaccord lowered the firm's price target on Quanterix (QTRX) to $15 from $20 and keeps a Buy rating on the shares. The firm said they continue to viewthe company as undervalued following the company's solid performance in 4Q24. That said, they recognize negative investor sentiment on its merger with Akoya Biosciences (AKYA) may negatively impact share price performance going forward.

Valuation Metrics

The current forward P/E ratio for Quanterix Corp (QTRX.O) is -4.28, compared to its 5-year average forward P/E of -15.99. For a more detailed relative valuation and DCF analysis to assess Quanterix Corp 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-15.99

Current PE

-4.28

Overvalued PE

-5.49

Undervalued PE

-26.48

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-11.68

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

1.08

Undervalued EV/EBITDA

-24.43

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

7.59

Current PS

0.00

Overvalued PS

13.89

Undervalued PS

1.28

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

QTRX News & Events

Events Timeline

No data

News

5.0

11-20Newsfilter

Quanterix Unveils Leadership and Board Changes to Facilitate Future Growth

9.0

11-17Newsfilter

Quanterix Unveils Pioneering Study Showcasing Dual GFAP/NfL Blood Test Method for Tailored Monitoring of Multiple Sclerosis

9.5

11-11NASDAQ.COM

Quanterix Corp Reports Wider Q3 Loss, Falls Short of Expectations

People Also Watch

Frequently Asked Questions

What is Quanterix Corp (QTRX) stock price today?

The current price of QTRX is 7.36 USD — it has decreased -0.67 % in the last trading day.

What is Quanterix Corp (QTRX)'s business?

Quanterix Corporation is engaged in fueling scientific discovery through ultra-sensitive biomarker detection. The Company’s Simoa technology delivers earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the level of quantification (LoQ). Its precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Its products and services include Simoa Assay Kits, Simoa Dry Blood Extraction Kit, LDTs & Assay Services, Instruments, Simoa Accelerator Laboratory, Homebrew-Custom Assay Development, and Nova Beads. LDTs & Assay Services include Simoa p-Tau 217, Simoa NfL LDT, and LucentAD pTau 217. Its instruments include Simoa HD-X Analyzer-Automated Immunoassays, Quanterix SR-X Biomarker Detection System, and SP-X Imaging and Analysis System.

What is the price predicton of QTRX Stock?

What is Quanterix Corp (QTRX)'s revenue for the last quarter?

Quanterix Corp revenue for the last quarter amounts to 40.23M USD, increased 12.34 % YoY.

What is Quanterix Corp (QTRX)'s earnings per share (EPS) for the last quarter?

Quanterix Corp. EPS for the last quarter amounts to -0.73 USD, increased 231.82 % YoY.

What changes have occurred in the market's expectations for Quanterix Corp (QTRX)'s fundamentals?

How many employees does Quanterix Corp (QTRX). have?

Quanterix Corp (QTRX) has 471 emplpoyees as of December 17 2025.

What is Quanterix Corp (QTRX) market cap?

Today QTRX has the market capitalization of 346.13M USD.